Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C

G. Firneisz, P. L. Lakatos, M. Horányi, A. Pár, Á Gógl, M. Abonyi, K. Dávid, J. Fehér, J. Gervain, E. Nemesánszky, Gy Tolvaj, G. Horváth, L. Telegdy, A. Csepregi, P. Ribiczey, B. Büki, E. Ibrányi, Zs Ozsvár, L. Pete, L. RókuszH. Osztrogonác, F. Szalay

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: DPP IV is a cell surface ectoenzyme widely distributed in the human body. It has been implicated in T-cell activation, hepatocyte-extracellular-matrix interactions and fibroblast proliferation. Furthermore, upregulated CD26 expression has been found on the surface of human hepatoma cells transfected with hepatitis C virus (HCV) c-DNA. We examined the serum DPP IV activity in a large number of patients with chronic HCV infection in a cross-sectional study. We also investigated whether the activity differs from that in controls and depends upon the response to interferon (IFN) therapy. Methods: Serum DPP IV activity was measured by microplate-based (Multiskan-Plus-MKII, Labsystem) kinetic assay in 144 patients with chronic HCV infection. Seventy-four out of 144 patients (46 non-responders, 28 responders) were formerly treated with interferon. Sixty healthy blood donors served as controls. Gly-Pro-PNA (Bachem, Torrance, USA) was used as substrate. Results are expressed in nmol/ml/min (U/l). Shapiro-Wilk's test, Mann-Whitney U test and Spearman rank order correlation were used for statistical analysis. Results: Serum DPP IV activity was significantly higher (mean = 20.89 [s 9.6]) in patients with chronic HCV infection than in healthy controls (12.39 [2.76, P < 10-5]). The enzyme activities significantly differed in naive HCV-positive patients (22.2 [9.89, P < 10-5]) and non-responders (23.28 [9.57, P < 10-5]) from that in the healthy controls and also from that in responders (13.69 [4.21]). Correlation was found between DPP IV activity and AST (r = 0.44, P < 10-5), ALT (r = 0.44, P < 10-5), GGT (r = 0.41, P < 10-5) levels. Conclusion: Serum DPP IV activity seems to be an indicator of HCV induced liver injury. The activity may reflect the efficacy of interferon therapy.

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalScandinavian journal of gastroenterology
Volume36
Issue number8
DOIs
Publication statusPublished - Jan 1 2001

    Fingerprint

Keywords

  • CD26
  • DPP IV
  • Dipeptidyl peptidase IV
  • HCV
  • Hepatitis
  • Interferon

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Firneisz, G., Lakatos, P. L., Horányi, M., Pár, A., Gógl, Á., Abonyi, M., Dávid, K., Fehér, J., Gervain, J., Nemesánszky, E., Tolvaj, G., Horváth, G., Telegdy, L., Csepregi, A., Ribiczey, P., Büki, B., Ibrányi, E., Ozsvár, Z., Pete, L., ... Szalay, F. (2001). Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scandinavian journal of gastroenterology, 36(8), 877-880. https://doi.org/10.1080/003655201750313423